Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
April 16, 2024 08:00 ET
|
Recursion Pharmaceuticals, Inc.
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development,...
Recursion Announces Plans to Open New Office in London
March 11, 2024 04:00 ET
|
Recursion Pharmaceuticals, Inc.
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new...
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
January 04, 2024 07:59 ET
|
Recursion Pharmaceuticals, Inc.
SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed...
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
November 09, 2023 08:01 ET
|
Recursion Pharmaceuticals, Inc.
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two...